SCHEMBL17276016

SCHEMBL17276016

COCCOc1cc(C(N)=O)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKBKB O14920 1/20 0.47
▸ CHEK2 O96017 2/20 0.44
▸ ACACB O00763 1/20 0.43
▸ CHEK1 O14757 1/20 0.42
▸ NNMT P40261 1/20 0.41
▸ OPRK1 P41145 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ LOXL2 Q9Y4K0 5/20 0.41
▸ LOX P28300 4/20 0.41
▸ HDAC1 Q13547 1/20 0.39
▸ HDAC6 Q9UBN7 1/20 0.39
▸ KCNK3 O14649 1/20 0.39
▸ KCNK9 Q9NPC2 1/20 0.39
▸ KDM4B O94953 1/20 0.39
▸ KDM5C P41229 1/20 0.39
▸ KDM5B Q9UGL1 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ AOC3 Q16853 1/20 0.39
▸ OPRM1 P35372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2585341 0.86 KDM4C (0.50) ACACBLOXL2KDM5CKDM5B
SCHEMBL30464945 0.86 KDM4C (0.50) ACACBLOXL2KDM5CKDM5B
SCHEMBL2590131 0.84 KDM4E (0.53) ACACBLOXL2LOXKCNK3KCNK9
SCHEMBL28575456 0.84 CHEK2 (0.44) IKBKBCHEK2CHEK1NNMTOPRK1
SCHEMBL6241029 0.82 PARP10 (0.51) IKBKBCHEK2ACACBNNMTOPRK1
SCHEMBL30281260 0.82 PARP10 (0.51) IKBKBCHEK2ACACBNNMTOPRK1
SCHEMBL201525 0.82 LMNA (0.48) OPRK1MAPK1HDAC6
SCHEMBL30281222 0.82 NNMT (0.56) NNMTOPRK1KCNH2MAPK1LOXL2
SCHEMBL445784 0.82 NNMT (0.56) NNMTOPRK1KCNH2MAPK1LOXL2
SCHEMBL6664238 0.81 OPRK1 (0.41) CHEK2NNMTOPRK1KCNH2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9771372-B2 Compounds useful as S100-inhibitors ACTIVE BIOTECH AB (SE) 2017-09-26 — — US disclosed
US-20170204098-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2017-07-20 — — US disclosed
EP-2991990-B1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2017-02-01 — — EP disclosed
EP-2991990-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS Active Biotech AB (SE) 2016-03-09 — — EP disclosed
WO-2015177367-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS ACTIVE BIOTECH AB (SE) 2015-11-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170204098-A1 NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS S100A9, S100A4, S100B IKBKB 740/4885CHEK2 2794/4885ACACB 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback